News
LivaNova to Announce Second-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A P
LivaNova Reports First-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.
Financial
LivaNova to Announce First-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays
LivaNova Reports Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February
LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administration (FDA) for the
LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S
LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its Chief Executive Officer Damien McDonald will present a general business update during
LivaNova Reports Third-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022.
Financial Summary and Highlights1
LivaNova to Announce Third-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third-quarter 2022 results on Wednesday, November 2, 2022, at 12
LivaNova Board Appoints Brooke Story as a New Director
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15
LivaNova Reports Second-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022.
Financial Summary and Highlights1
-
Revenue
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit
LivaNova to Announce Second-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1
LivaNova Elects Peter Wilver to Board of Directors
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of
LivaNova to Present at the Goldman Sachs Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Goldman
LivaNova Reports First-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.
Financial Summary and Highlights1